211 related articles for article (PubMed ID: 17483928)
21. Hormonal prevention of prostate cancer.
Brawley OW
Urol Oncol; 2003; 21(1):67-72. PubMed ID: 12684130
[TBL] [Abstract][Full Text] [Related]
22. Chemoprevention of prostate cancer.
Klein EA
Annu Rev Med; 2006; 57():49-63. PubMed ID: 16409136
[TBL] [Abstract][Full Text] [Related]
23. Chemotherapeutic prevention studies of prostate cancer.
Djavan B; Zlotta A; Schulman C; Teillac P; Iversen P; Boccon Gibod L; Bartsch G; Marberger M
J Urol; 2004 Feb; 171(2 Pt 2):S10-3; discussion S13-4. PubMed ID: 14713746
[TBL] [Abstract][Full Text] [Related]
24. Prevention strategies for prostate cancer.
Schmitz-Dräger BJ; Lümmen G; Bismarck E; Fischer C
Minerva Urol Nefrol; 2012 Dec; 64(4):225-31. PubMed ID: 23288209
[TBL] [Abstract][Full Text] [Related]
25. Stat bite: Estimated effect of finasteride on prostate cancer development.
J Natl Cancer Inst; 2003 Jul; 95(14):1031. PubMed ID: 12865443
[No Abstract] [Full Text] [Related]
26. Finasteride, a selective 5-alpha-reductase inhibitor, in the prevention and treatment of human prostate cancer.
Reddy GK
Clin Prostate Cancer; 2004 Mar; 2(4):206-8. PubMed ID: 15072601
[No Abstract] [Full Text] [Related]
27. Battling prostate cancer with 5-alpha-reductase inhibitors: a pyrrhic victory?
Hoffman RM; Roberts RG; Barry MJ
J Gen Intern Med; 2011 Jul; 26(7):798-801. PubMed ID: 21222171
[TBL] [Abstract][Full Text] [Related]
28. Chemoprevention of prostate cancer with finasteride.
Thompson I; Feigl P; Coltman C
Important Adv Oncol; 1995; ():57-76. PubMed ID: 7672814
[No Abstract] [Full Text] [Related]
29. Prostate cancer prevention with 5 alpha-reductase inhibitors.
Parekh DJ
Recent Results Cancer Res; 2011; 188():109-14. PubMed ID: 21253793
[No Abstract] [Full Text] [Related]
30. The Prostate Cancer Prevention Trial and the future of chemoprevention.
Thompson IM; Tangen CM; Lucia MS
BJU Int; 2008 Apr; 101(8):933-4. PubMed ID: 18353157
[No Abstract] [Full Text] [Related]
31. [Relevance of chemoprevention from PCPT trial].
Irani J
Prog Urol; 2008 Apr; 18 Suppl 3():S63-5. PubMed ID: 18455087
[TBL] [Abstract][Full Text] [Related]
32. Prostate cancer prevention agent development: Criteria and pipeline for candidate chemoprevention agents.
Nelson WG; Wilding G
Urology; 2001 Apr; 57(4 Suppl 1):56-63. PubMed ID: 11295596
[TBL] [Abstract][Full Text] [Related]
33. The potential application of finasteride for chemoprevention of prostate cancer.
Gormley GJ; Brawley O; Thompson I
Ann N Y Acad Sci; 1995 Sep; 768():163-9. PubMed ID: 8526345
[No Abstract] [Full Text] [Related]
34. The chemoprevention of prostate cancer and the Prostate Cancer Prevention Trial.
Brawley OW; Thompson IM
Cancer Treat Res; 1996; 88():189-200. PubMed ID: 9239480
[No Abstract] [Full Text] [Related]
35. Finasteride for chemoprevention of prostate cancer: why has it not been embraced?
de Vere White RW
J Clin Oncol; 2007 Jul; 25(21):2999-3000. PubMed ID: 17634478
[No Abstract] [Full Text] [Related]
36. The risks and benefits of 5α-reductase inhibitors for prostate-cancer prevention.
Theoret MR; Ning YM; Zhang JJ; Justice R; Keegan P; Pazdur R
N Engl J Med; 2011 Jul; 365(2):97-9. PubMed ID: 21675880
[No Abstract] [Full Text] [Related]
37. Finasteride.
Chaudhary UB; Turner JS
Expert Opin Drug Metab Toxicol; 2010 Jul; 6(7):873-81. PubMed ID: 20536414
[TBL] [Abstract][Full Text] [Related]
38. Prevention of prostate cancer.
DePrimo SE; Shinghal R; Vidanes G; Brooks JD
Hematol Oncol Clin North Am; 2001 Jun; 15(3):445-57. PubMed ID: 11525290
[TBL] [Abstract][Full Text] [Related]
39. Toremifene--a promising therapy for the prevention of prostate cancer and complications of androgen deprivation therapy.
Taneja SS; Smith MR; Dalton JT; Raghow S; Barnette G; Steiner M; Veverka KA
Expert Opin Investig Drugs; 2006 Mar; 15(3):293-305. PubMed ID: 16503765
[TBL] [Abstract][Full Text] [Related]
40. [The PCPT trial].
Hamdy FC; Rouprêt M
Prog Urol; 2008 Apr; 18 Suppl 3():S40-3. PubMed ID: 18455082
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
